Compare RM & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RM | LCTX |
|---|---|---|
| Founded | 1987 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 302.1M | 251.4M |
| IPO Year | 2011 | 1996 |
| Metric | RM | LCTX |
|---|---|---|
| Price | $36.80 | $1.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $43.83 | $5.50 |
| AVG Volume (30 Days) | 81.0K | ★ 1.4M |
| Earning Date | 10-28-2026 | 11-09-2026 |
| Dividend Yield | ★ 3.57% | N/A |
| EPS Growth | ★ 7.49 | N/A |
| EPS | ★ 2.03 | N/A |
| Revenue | ★ $645,598,000.00 | $14,556,000.00 |
| Revenue This Year | $10.44 | $4.38 |
| Revenue Next Year | $6.37 | $10.80 |
| P/E Ratio | $16.61 | ★ N/A |
| Revenue Growth | 9.70 | ★ 53.24 |
| 52 Week Low | $29.89 | $0.88 |
| 52 Week High | $44.30 | $2.09 |
| Indicator | RM | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 68.67 | 56.23 |
| Support Level | $33.51 | $1.02 |
| Resistance Level | $38.08 | $1.05 |
| Average True Range (ATR) | 1.29 | 0.06 |
| MACD | 0.17 | 0.01 |
| Stochastic Oscillator | 73.43 | 85.28 |
Regional Management Corp is a diversified consumer finance company that provides installment loan products to customers with limited access to consumer credit from banks, thrifts, credit card companies, and other lenders. The company is engaged in consumer finance. The company has the core products which are small and large installment loans. The company also offers optional payment and collateral protection insurance. The company's principal source of revenue is interest and fee income on outstanding loans.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.